Morgan Stanley Reiterates Equal-Weight on Revance Therapeutics, Maintains $26 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has reiterated an Equal-Weight rating on Revance Therapeutics (NASDAQ:RVNC) and maintained a $26 price target.
July 11, 2023 | 1:41 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has reiterated an Equal-Weight rating on Revance Therapeutics and maintained a $26 price target.
The news is directly about Revance Therapeutics and its rating by Morgan Stanley. The reiteration of the Equal-Weight rating and the maintenance of the $26 price target suggests that Morgan Stanley's view on the company has not changed. This is likely to have a neutral impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100